| Literature DB >> 34960081 |
José Almeida1,2, Tiago Ferreira1,2, Susana Santos1,2, Maria J Pires1,2, Rui M Gil da Costa2,3,4,5, Rui Medeiros5,6,7,8, Margarida M S M Bastos4, Maria J Neuparth9,10, Ana I Faustino-Rocha1,11, Helena Abreu12, Rui Pereira12,13, Mário Pacheco14, Isabel Gaivão15, Eduardo Rosa2,16, Paula A Oliveira1,2.
Abstract
The role of dietary profiles in promoting or reducing the risk of multiple types of cancer is increasingly clear, driving the search for balanced foods and nutraceuticals. The red seaweed Grateloupia turuturu has been used as human food showing a balanced nutritional profile. This study aims to test in vivo chemopreventive effects of G. turuturu against cutaneous pre-malignant lesions in transgenic mice for the human papillomavirus type 16 (HPV16). Forty-four female HPV+/- or HPV-/- mice received a standard diet or were supplemented with 10% G. turuturu for 22 consecutive days. Cutaneous lesions (ear and chest skin) were identified histologically. Complementarily, the weights and histology of internal organs as well as blood biochemical and DNA integrity parameters were also assessed. G. turuturu consistently reduced the incidence of epidermal dysplasia induced by HPV16 on both cutaneous sites. Moreover, biochemical, DNA integrity and histological analyses confirmed G. turuturu edibility as no signs of toxicity were found. Dietary supplementation with G. turuturu is an effective and safe chemopreventive strategy in this model.Entities:
Keywords: HPV; chemoprevention; functional foods; in vivo; natural products; supplementation
Mesh:
Substances:
Year: 2021 PMID: 34960081 PMCID: PMC8707361 DOI: 10.3390/nu13124529
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Relative weight (g/g) of collected organs in experimental groups (mean ± standard error).
|
| Standard Diet | |||
|---|---|---|---|---|
| Group I | Group II | Group III | Group IV | |
| Liver | 0.0609 ± 0.0013 | 0.0688 ± 0.0049 | 0.0574 ± 0.0012 | 0.0717 ± 0.0185 |
| Right Kidney | 0.0063 ± 0.0001 | 0.0069 ± 0.0002 | 0.0057 ± 0.0002 | 0.0069 ± 0.0002 |
| Left Kidney | 0.0067 ± 0.0001 | 0.0070 ± 0.0003 | 0.0062 ± 0.0002 | 0.0068 ± 0.0002 |
| Thymus | 0.0012 ± 0.0001 | 0.0012 ± 0.0001 | 0.0012 ± 0.0002 | 0.0014 ± 0.0001 |
| Heart | 0.0048 ± 0.0001 | 0.0049 ± 0.0002 | 0.0048 ± 0.0002 | 0.0051 ± 0.0002 |
| Lungs | 0.0065 ± 0.0003 | 0.0060 ± 0.0004 | 0.0063 ± 0.0003 | 0.0071 ± 0.0002 |
| Bladder | 0.0086 ± 0.0070 | 0.0009 ± 0.0001 | 0.0003 ± 0.0002 | 0.0008 ± 0.0001 |
| Spleen | 0.0052 ± 0.0003 | 0.0066 ± 0.0005 | 0.0047 ± 0.0002 | 0.0083 ± 0.0010 |
Serum biochemical parameters analyzed (mean ± standard error).
|
| Standard Diet | |||
|---|---|---|---|---|
| Group I | Group II | Group III | Group IV | |
| Albumin (g/L) | 31.48 ± 0.69 | 30.64 ± 0.75 | 29.78 ± 1.71 | 30.37 ± 0.96 |
| Total proteins (g/L) | 50.11 ± 2.04 | 53.65 ± 1.63 | 51.34 ± 4.07 | 49.62 ± 1.12 |
| Glucose (mg/dL) | 234.96 ± 17.92 | 185.75 ± 9.06 | 195.70 ± 15.99 | 198.07 ± 13.36 |
| Alanine aminotransferase (U/L) | 30.77 ± 5.32 | 36.59 ± 4.27 | 37.28 ± 4.70 | 41.87 ± 3.54 |
| Aspartate aminotransferase (U/L) | 64.96 ± 8.31 | 67.03 ± 8.45 | 44.74 ± 3.76 | 51.82 ± 3.70 |
| Gamma-glutamyl transferase (U/L) | 33.39 ± 3.70 | 36.75 ± 4.00 | 48.61 ± 6.11 | 60.78 ± 8.35 |
Incidence of histological lesions in chest and ear skin in the four experimental groups.
| Standard Diet | |||||
|---|---|---|---|---|---|
| Group I | Group II | Group III | Group IV | ||
| Chest skin affected mice/n | Normal | 11/11 | 0/10 | 11/11 | 0/11 |
| Epidermal Hyperplasia | 0/11 | 8/10 | 0/11 | 4/11 | |
| Epidermal Dysplasia | 0/11 | 2/10 | 0/11 | 7/11 | |
| Ear | Normal | 11/11 | 0/10 | 11/11 | 0/11 |
| Epidermal Hyperplasia | 0/11 | 9/10 | 0/11 | 4/11 | |
| Epidermal Dysplasia | 0/11 | 1/10 | 0/11 | 7/11 | |
a Statistically significant difference between group II and group IV (p < 0.05).
Figure 1Analysis of DNA damage. (A) Mean ± standard deviation values of non-specific damage, expressed as genetic damage index (GDI, grey), and of non-specific plus oxidative damage, determined with formamidopyrimidine DNA glycosilase (FPG) and expressed as GDIFPG (black), in white blood cells (n = 11/group). (B) Values of net FPG-sensitive sites (NSSFPG) from modified comet assay with FPG incubation to detect oxidized purine bases (obtained by the difference between GDIFPG and GDI values). Statistically significant differences (p < 0.05): (a) Between group I and group III; (b) between group II and group IV.
Figure 2Frequency of micronuclei per 1000 erythrocytes (mean ± standard deviation; n = 11, two replicates per animal).